| 1 |
Bu BT , Li Y . Myotonic dystrophy. Zhonghua Shen Jing Ke Za Zhi, 2019, 52: 654- 658.
|
|
卜碧涛, 李悦. 强直性肌营养不良. 中华神经科杂志, 2019, 52: 654- 658.
|
| 2 |
Yanovsky-Dagan S , Cohen E , Megalli P , Altarescu G , Schonberger O , Eldar-Geva T , Epsztejn-Litman S , Eiges R . DMPK hypermethylation in sperm cells of myotonic dystrophy type 1 patients. Eur J Hum Genet, 2022, 30: 980- 983.
doi: 10.1038/s41431-021-00999-3
|
| 3 |
Furling D . Misregulation of alternative splicing and microRNA processing in DM1 pathogenesis. Rinsho Shinkeigaku, 2012, 52: 1018- 1022.
doi: 10.5692/clinicalneurol.52.1018
|
| 4 |
Wu XL , Zhang AN , Lei XY , Feng ZH , Wang W , He D . Myotonic dystrophy type 1: one case report. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2023, 23: 765- 769.
|
|
吴旭玲, 张安妮, 雷晓阳, 冯占辉, 王维, 贺电. 强直性肌营养不良症1型一例. 中国现代神经疾病杂志, 2023, 23: 765- 769.
|
| 5 |
Rashed HR , Milone M . The spectrum of rippling muscle disease. Muscle Nerve, 2025, 71: 9- 21.
doi: 10.1002/mus.28270
|
| 6 |
Fujikawa H , Hayashi D , Sato M . Myotonic dystrophy type 1: a snap diagnosis during a medical checkup. Am J Med Sci, 2022, 364: e8- e9.
|
| 7 |
Wu YF , Zhou ZH , Han YZ , Wang X , Yu XE , Han YS , Shi YG . Clinical, electrophysiological and muscular pathological manifestation of myotonic dystrophy. Zhongguo Lin Chuang Shen Jing Ke Xue, 2013, 21: 70- 74.
|
|
吴筠凡, 周志华, 韩咏竹, 王训, 喻绪恩, 韩永升, 石永光. 强直性肌营养不良临床、电生理和肌肉病理研究. 中国临床神经科学, 2013, 21: 70- 74.
|
| 8 |
Dang JX . Electromyography diagnosis and clinical application. Beijing: People's Medical Publishing House, 2005: 106- 109.
|
|
党静霞. 肌电图诊断与临床应用. 北京: 人民卫生出版社, 2005: 106- 109.
|
| 9 |
Lu ZN , Zeng QX , Li CY , Yu SZ . Practical electromyography. Beijing: People's Medical Publishing House, 2000: 458- 460.
|
|
卢祖能, 曾庆杏, 李承晏, 余绍祖. 实用肌电图学. 北京: 人民卫生出版社, 2000: 458- 460.
|
| 10 |
Zhang RR , Wang SH , Bai YY , Zhang JW , Zhang HJ . Dystrophia myotonia type 1 with excessive daytime sleepiness: one case report. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2020, 20: 659- 662.
|
|
张蕊蕊, 王升辉, 白莹莹, 张杰文, 张红菊. 伴白天过度嗜睡的Ⅰ型强直性肌营养不良症一例. 中国现代神经疾病杂志, 2020, 20: 659- 662.
|
| 11 |
Kubota T , Nakamori M , Takahashi MP . Myotonia and cardiac conduction defects in myotonic dystrophy and defect in ion channels. Rinsho Byori, 2014, 62: 246- 254.
|
| 12 |
McGowan BR , Schwaede AN , De Simone L , Rao VK . Muscle channelopathies: a review. Ann Child Neurol Soc, 2023, 1: 273- 288.
doi: 10.1002/cns3.20040
|
| 13 |
Bashford J , Chan WK , Coutinho E , Norwood F , Mills K , Shaw CE . Demystifying the spontaneous phenomena of motor hyperexcitability. Clin Neurophysiol, 2021, 132: 1830- 1844.
doi: 10.1016/j.clinph.2021.03.053
|
| 14 |
Abdulla AJ , Jones PW , Pearce VR . Leg cramps in the elderly: prevalence, drug and disease associations. Int J Clin Pract, 1999, 53: 494- 496.
doi: 10.1111/j.1742-1241.1999.tb11786.x
|
| 15 |
Minetto MA , Holobar A , Botter A , Farina D . Origin and development of muscle cramps. Exerc Sport Sci Rev, 2013, 41: 3- 10.
doi: 10.1097/JES.0b013e3182724817
|
| 16 |
Triplett JD , Shelly S , Livne G , Milone M , Kassardjian CD , Liewluck T , Kelly C , Naddaf E , Laughlin RS , Lamb CJ , Rubin D , Dimberg EL , Dubey D , Mills JR , Mandrekar J , Klein CJ . Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia. Brain Commun, 2020, 2: fcaa191.
doi: 10.1093/braincomms/fcaa191
|
| 17 |
Engel WK . Myotonia: a different point of view. Calif Med, 1971, 114: 32- 37.
|
| 18 |
Sadeh M , Dabby R . Steroid-responsive myopathy: immune-mediated necrotizing myopathy or polymyositis without inflammation?. J Clin Neuromuscul Dis, 2008, 9: 341- 344.
doi: 10.1097/CND.0b013e31815e5d4a
|
| 19 |
Hermans MC , Faber CG , Vanhoutte EK , Bakkers M , De Baets MH , de Die-Smulders CE , Merkies IS . Peripheral neuropathy in myotonic dystrophy type 1. J Peripher Nerv Syst, 2011, 16: 24- 29.
|
| 20 |
Bae JS , Kim OK , Kim SJ , Kim BJ . Abnormalities of nerve conduction studies in myotonic dystrophy type 1: primary involvement of nerves or incidental coexistence?. J Clin Neurosci, 2008, 15: 1120- 1124.
doi: 10.1016/j.jocn.2007.11.002
|
| 21 |
Peric S , Stojanovic VR , Nikolic A , Kacar A , Basta I , Pavlovic S , Lavrnic D . Peripheral neuropathy in patients with myotonic dystrophy type 1. Neurol Res, 2013, 35: 331- 335.
doi: 10.1179/1743132812Y.0000000144
|
| 22 |
Spaziani M , Semeraro A , Bucci E , Rossi F , Garibaldi M , Papassifachis MA , Pozza C , Anzuini A , Lenzi A , Antonini G , Radicioni AF . Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study. J Endocrinol Invest, 2020, 43: 663- 675.
doi: 10.1007/s40618-019-01156-w
|
| 23 |
Ivanovic V , Meola G , Vukojevic Z , Peric S . Update on therapy for myotonic dystrophy type 1. Curr Treat Options Neurol, 2023, 25: 261- 279.
doi: 10.1007/s11940-023-00760-9
|
| 24 |
Aoki Y , Wood MJA . Emerging oligonucleotide therapeutics for rare neuromuscular diseases. J Neuromuscul Dis, 2021, 8: 869- 884.
doi: 10.3233/JND-200560
|
| 25 |
Timchenko L . Development of therapeutic approaches for myotonic dystrophies type 1 and type 2. Int J Mol Sci, 2022, 23: 10491.
doi: 10.3390/ijms231810491
|
| 26 |
Fowler M , Johnson N , Thornton C , Day J , Sansone V , McEvoy B , Tai L , Knisely B , Brandt T , Gallagher K , Hughes S , Ackermann E . Phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of myotonic dystrophy type 1: HARBOR trial design. Neuromuscular Disorders, 2024, 43 Suppl: 104441.
|
| 27 |
Horrigan JP , Snape M , Fantelli E . The efficacy and safety of Tideglusib in a randomized, placebo-controlled, double blind study in children and adolescents with congenital myotonic dystrophy (REACH CDM study). Neuromuscular Disorders, 2023, 33: S70- S71.
|
| 28 |
|
| 29 |
Pascual-Gilabert M , Artero R , López-Castel A . The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Drug Discov Today, 2023, 28: 103489.
doi: 10.1016/j.drudis.2023.103489
|
| 30 |
Wahbi K , Bassez G , Duchateau J , Salort-Campana E , Vicart S , Desaphy JF , Labombarda F , Sellal JM , Deharo JC . Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy. Arch Cardiovasc Dis, 2024, 117 (6/7): 450- 456.
|
| 31 |
Timchenko L . Myotonic dystrophy: from molecular pathogenesis to therapeutics. Int J Mol Sci, 2022, 23: 11954.
doi: 10.3390/ijms231911954
|
| 32 |
García-Puga M , Saenz-Antoñanzas A , Matheu A , López de Munain A . Targeting myotonic dystrophy type 1 with metformin. Int J Mol Sci, 2022, 23: 2901.
doi: 10.3390/ijms23052901
|
| 33 |
Ravel-Chapuis A , Duchesne E , Jasmin BJ . Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients. J Physiol, 2022, 600: 3249- 3264.
doi: 10.1113/JP282725
|
| 34 |
Bassez G , Audureau E , Hogrel JY , Arrouasse R , Baghdoyan S , Bhugaloo H , Gourlay-Chu ML , Le Corvoisier P , Peschanski M . Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. Brain, 2018, 141: 2855- 2865.
doi: 10.1093/brain/awy231
|
| 35 |
Lutz M , Levanti M , Karns R , Gourdon G , Lindquist D , Timchenko NA , Timchenko L . Therapeutic targeting of the GSK3β-CUGBP1 pathway in myotonic dystrophy. Int J Mol Sci, 2023, 24: 10650.
doi: 10.3390/ijms241310650
|
| 36 |
Marcella BM , Hockey BL , Braun JL , Whitley KC , Geromella MS , Baranowski RW , Watson CJF , Silvera S , Hamstra SI , Wasilewicz LJ , Crozier RWE , Marais AAT , Kim KH , Lee G , Vandenboom R , Roy BD , MacNeil AJ , MacPherson REK , Fajardo VA . GSK3 inhibition improves skeletal muscle function and whole-body metabolism in male mouse models of Duchenne muscular dystrophy. Nat Commun, 2024, 15: 10210.
doi: 10.1038/s41467-024-53886-y
|
| 37 |
Izzo M , Battistini J , Provenzano C , Martelli F , Cardinali B , Falcone G . Molecular therapies for myotonic dystrophy type 1: from small drugs to gene editing. Int J Mol Sci, 2022, 23: 4622.
doi: 10.3390/ijms23094622
|
| 38 |
Na S , Lee ES , Kim YD , Lee TK . Slowly progressive ophthalmoplegia as a presenting symptom of myotonic dystrophy type 1. J Neuroophthalmol, 2021, 41: e741- e742.
doi: 10.1097/WNO.0000000000001132
|